ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 374. Ribeiro HB, Lerakis S, GilardM, Cavalcante JL, Makkar R, Herrmann HC, et al. Transcatheter aortic valve replacement in patients with low-flow, low-gradient aortic stenosis: the TOPAS-TAVI registry. J Am Coll Cardiol. 2018;71(12):1297-308. 375. Kjekshus J, Pedersen TR, Olsson AG, FaergemanO, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3(4):249-54. Erratum in: J Card Fail 1998;4(4):367. 376. Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R; Heart Protection Study Collaborative Group. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection Study. J Am Coll Cardiol. 2007;49(3):311-9. 377. Mills EJ, Rachlis B,Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769-81. 378. Fröhlich H, Raman N, Schellberg D, Goode KM, Kazmi S, et al. Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol inpatientswithnon-ischemicchronicheart failure.Int JCardiol. 2017 Jul 1;238:97-104. 379. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61. 380. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI- HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-9. 381. Rossi A, Inciardi RM, Rossi A, Temporelli PL, Lucci D, Gonzini L, et al. Prognostic effects of rosuvastatin in patients with co-existing chronic obstructive pulmonary disease and chronic heart failure: a sub-analysis of GISSI-HF trial. Pulm Pharmacol Ther. 2017 Jun;44:16-23. 382. Bakakos A, Oikonomou E, Vogiatzi G, Siasos G, Tsalamandris S, Antonopoulos A, et al. Statins and left ventricular function. Curr Pharm Des. 2017 Sep 26. [Epub ahead of print]. 383. Bayes-Genis A, Núñez J, Zannad F, Ferreira JP, Anker SD, Cleland JG, et al. The PCSK9-LDL Receptor axis and outcomes in heart failure: BIOSTAT- CHF Subanalysis. J Am Coll Cardiol. 2017;70(17):2128-36. 384. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al; CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program Circulation. 2007;116(6):627-36. 385. Kapoor JR, Heidenreich PA. Obesity and survival in patients with heart failure and preserved systolic function: aU-shaped relationship. AmHeart J. 2010;159(1):75-80. 386. Ingelsson E, Sundström J, Arnlöv J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA. 2005;294(3):334-41. 387. Simao AF, Precoma DB, Andrade JP, Correa Filho H, Saraiva JF, Oliveira GM, et al; Sociedade Brasileira de Cardiologia. [I Brazilian Guidelines for cardiovascular prevention]. Arq Bras Cardiol. 2013;101 (6 Suppl 2):1-63. 388. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR), ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012;33(13):1635-701. 389. von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers. Update 2014. J Cachexia Sarcopenia Muscle. 2014;5(4):261-3. 390. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121(3):227-52. 391. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology. Update 2014. J Cachexia Sarcopenia Muscle. 2014;5(4):253-9. 392. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al; American College of Cardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327. 393. Sharma A, Ezekowitz JA. Diabetes, impaired fasting glucose, and heart failure: it’s not all about the sugar. Eur J Heart Fail. 2014;16(11):1153-6. 394. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879-84. 395. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005;28(3):612-6. 396. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff Jr DC. Heart failure prevalence, incidence, andmortality in the elderly with diabetes. Diabetes Care . 2004;27(3):699-703. 397. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86. 398. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53. 399. GersteinHC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et al; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-28. 400. MacDonald MR, Eurich DT, Majumdar SR, Lewsy JD, Bhagra S, Jhund OS, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. 2010;33(6):1213-8. 401. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012;9(4):e1001204. 402. Faludi AA, Izar MC, Saraiva JF, Bianco HT, Chacra AP, Bertoluci MC et al. Diretriz brasileira baseada em evidências sobre prevenção de doenças cardiovasculares em pacientes com diabetes: posicionamento da Sociedade Brasileira de Diabetes (SBD), da Sociedade Brasileira de Cardiologia (SBC) e da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM). Arq Bras Cardiol. 2017;109(6 Suppl 1):1-31. 403. Rados DV, Pinto LC, Remonti LR, Leitao CB, Gross JL. Correction: the association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016;13(6):e1002091. 404. KomajdaM, McMurray JJ, Beck-NielsenH, Gomis R, HanefeldM, Pocock SJ, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824-31. 405. HernandezAV,UsmaniA,RajamanickamA,MoheetA.Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus:ameta-analysisandmeta-regressionanalysisofplacebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115-28. 528